AB Science S.A. (ABSCF)
- Globe Newswire
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS STARTED THE REVIEW OF NEW DRUG SUBMISSION FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS), FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER Paris, 26 May, 2022, 10pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), meaning that the information and mat
- Globe Newswire
AB Science reports its revenues for the year 2021 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2021 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis under the NOC/c policyPublication of new long-term data showing that masitinib extended survival in amyotrophic lateral sclerosis by 25 months, provided that treatment starts early in disease courseContinuation of the development program
- Globe Newswire
AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN IN COVID-19 Paris, 28 April 2022, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB). This randomized (1:1), open-label, phase 2 study (AB2
